S&P 500 slips as Gilead weighs

The S&P 500 ended marginally lower on Thursday after a report that an experimental antiviral drug for the coronavirus flopped in its first randomized clinical trial, denting earlier optimism the impact of the virus on the labor market was nearing an end.


See also  Trump will nominate a woman next week to succeed Ginsburg on Supreme Court By Reuters

Leave a Reply

This website uses cookies. By continuing to use this site, you accept our use of cookies.